Trial Holdings Aktie 125610996 / JP3635490000
| Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
|---|---|---|---|---|---|---|
| Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
| Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Trading-Depot | Watchlist |
| Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
| Historisch | Analysen | |||||
Kurse + Charts + Realtime
News + Analysen
Fundamental
zugeh. Wertpapiere
|
28.09.2025 16:15:00
|
Are These GLP-1 Trial Results About to Send Eli Lilly's Stock Soaring?
Over the past five years, Eli Lilly (NYSE: LLY) has outperformed the broader market, largely thanks to its progress in the GLP-1 arena. Its major breakthroughs in the field are already leading to incredible commercial success.But Lilly isn't done just yet. Recent clinical developments may set the stage for further stock-market gains, and potentially allow the drugmaker to maintain that momentum through the end of the decade. Let's find out what Eli Lilly has been up to, and what that means for investors.Eli Lilly's tirzepatide, marketed under the brands Mounjaro for diabetes and Zepbound for weight management, is highly effective -- and generating billions of dollars in sales per quarter already. However, the medicine is administered subcutaneously once a week. This route has several drawbacks compared to oral pills.Continue readingWeiter zum vollständigen Artikel bei MotleyFool